Genmab A/S announced DARZALEX sales results for the first quarter of 2024. For the quarter, the company reported net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 million. Net trade sales were USD 1,464 million in the U.S. and USD 1,228 million in the rest of the world.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,970 DKK | +0.79% | -2.96% | -8.58% |
Apr. 29 | Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug | DJ |
Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.58% | 18.15B | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B | |
-24.98% | 8.24B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024